Q1 EPS Estimate for Werewolf Therapeutics Lowered by Analyst

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Equities researchers at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Werewolf Therapeutics in a research report issued on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.43) for the quarter, down from their prior forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Werewolf Therapeutics’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($1.56) EPS, FY2028 earnings at ($1.07) EPS and FY2029 earnings at ($0.64) EPS.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

A number of other brokerages have also recently weighed in on HOWL. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday, March 12th. JMP Securities dropped their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th.

Werewolf Therapeutics Trading Down 2.5 %

Shares of HOWL stock opened at $1.17 on Monday. Werewolf Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $6.89. The stock has a market cap of $52.45 million, a P/E ratio of -0.76 and a beta of 0.37. The business has a fifty day simple moving average of $1.34 and a 200-day simple moving average of $1.79. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. PFM Health Sciences LP boosted its stake in Werewolf Therapeutics by 4.9% in the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after buying an additional 157,673 shares during the last quarter. Geode Capital Management LLC boosted its stake in Werewolf Therapeutics by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock worth $1,040,000 after buying an additional 16,569 shares during the last quarter. State Street Corp boosted its stake in Werewolf Therapeutics by 12.4% in the 3rd quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares during the last quarter. Northern Trust Corp boosted its stake in Werewolf Therapeutics by 7.3% in the 4th quarter. Northern Trust Corp now owns 244,390 shares of the company’s stock worth $362,000 after buying an additional 16,640 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its stake in Werewolf Therapeutics by 24.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company’s stock worth $162,000 after buying an additional 21,500 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.